Researchers Propose New Treatment For Adult Respiratory Distress Syndrome
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Researchers Propose New Treatment For Adult Respiratory Distress Syndrome

LONDON, ENGLAND -- April 9, 1999 -- In a study in this week's issue of The Lancet, researchers have found that in the patients with adult respiratory distress syndrome (ARDS) an essential protein found in lung surfactant -- called specific-protein A -- is damaged. This discovery could lead to the development of new treatments for this syndrome.

ARDS occurs when inflammation damages the lung and can be caused by direct injury to the lung, such as that caused by smoke inhalation, or by inflammation triggered by damage, such as trauma, occurring elsewhere in the body. This inflammation initiates a reaction called surfactant failure. Surfactant is a mixture of chemicals, produced by cells in the lung, which reduces the surface tension of the fluid lining the air sacs, making it possible for the air sacs to remain open between breaths.

In surfactant failure, the air sacs collapse, so the lung cannot function properly in providing oxygenated blood to the rest of the body. This leads to ARDS and, unless the condition is reversed, the patient will suffocate. Currently, about 40 percent of patients who develop ARDS die as a result of the disorder.

Although artificial surfactants are known to improve lung function in infants with respiratory distress syndrome, a syndrome which occurs in premature infants born before their lungs can produce enough of their own surfactant, in ARDS patients, the effect of artificial surfactants is short-lived.

Dr. Cathy Baker and co-workers from Britain's National Heart and Lung Institute studied surfactant taken from the lungs of 18 patients with adult respiratory distress syndrome (ARDS) and compared it with surfactant taken from six healthy volunteers. Their findings indicate that protein-cutting enzymes, called proteases, produced by white cells activated by the inflammation are snipping specific-protein A into fragments. This could explain why artificial surfactant treatments fail in ARDS patients and has given scientists a greater understanding of this disorder.

The researchers conclude that giving drugs to protect specific-protein A in the lungs from damage from proteases may help patients and added that a combination of surfactant and antiprotease therapy may improve therapeutic prospects.

Related Link: The Lancet

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities